SEARCH:   Advanced

Erratum for Moreaux et al., Blood 108 (13) 4194-4197. Blood, 1 April 2007, Vol. 109, No. 7, pp. 2717. This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Search for Related Content Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  ERRATUM Erratum in Moreaux et al. CD200 is a new prognostic factor in multiple myeloma. In the article by Moreaux et al entitled "CD200 is a new prognostic factor in multiple myeloma," which appeared in the December 15, 2006, issue of Blood (Volume 108:4194-4197), the event-free survival values were not supported by the Kaplan-Meier plot of Figure 1C. We made a mistake using survival data of a preliminary version of that paper with a reduced patient cohort. With the cohort of 112 patients used in the paper, the median event-free survival (EFS) was 20 months for the CD200present group and not reached for the CD200absent group. These data could be improved with a recent update of patients' survival. EFS is now 25 months for the CD200present group and 44 months for the CD200absent group (P = .04) (revised Figure 1C). Regarding ISS, it was not used to predict EFS in Greipp et al.20 In our study, events were defined as relapse, progressive disease, or death for autologous transplantation. For patients with allogenic transplantation, the EFS was censored 4 weeks after autologous transplantation. In our study, ISS proved to be predictive for both OS (P = .078) and EFS (P = .001) (new Figure 2). The median EFS was 47 months for stage 1, 25 months for stage 2, and 12 months for stage 3 (P = .001). CD200 expression and ISS staging were independently predictive for EFS when they were entered in a Cox-proportional hazard model with a 2.27 hazard ratio for CD200 expression and 1.91 for ISS staging. View larger version (26K): [in this window] [in a new window]   Figure 1. Kaplan-Meier plot of the event-free survival in patients with CD200present and CD200absent MMCs.   View larger version (27K): [in this window] [in a new window]   Figure 2. Kaplan-Meier plots of the overall and event-free survivals in our cohort of 112 patients according to ISS stage.      Reference Top Reference   Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23:3412–3420.[Abstract/Free Full Text] CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Search for Related Content Social Bookmarking                   What's this?

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020